Answers are grounded in this paper and cite their sources.
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in patients with advanced chronic kidney disease (CKD), yet its impact on economic and humanistic burden remains insufficiently characterized. We aimed to systematically review the published literature reporting economic outcomes, healthcare resource utilization (HRU), and humanistic impact of the association between advanced CKD and CVD. A systematic literature review (SLR) was conducted using MEDLINE, Embase, Cochrane databases, and conference abstracts to identify evidence published between 2020 and December 31, 2025. Studies reporting economic or humanistic burden outcomes among adults with CKD G4–G5 or kidney failure and coexisting cardiovascular conditions were included. In total, 6350 records were screened, with 87 studies meeting inclusion criteria. Across studies, coexisting CVD markedly increased costs and HRU in advanced CKD. In the USA, the costs per event ranged from $12,410 USD for systolic heart failure to $92,898 for chronic heart failure. Compared to CKD G4, patients in G5 incurred higher annual per patient hospitalization costs (77%), outpatient costs (65%), and total healthcare costs (61% (US) to 64% (non-US)). Emergency visits, intensive care unit (ICU) admissions, and rehospitalizations were more frequent among patients with coexisting CVD and advanced CKD compared to those without CVD, with 30-day readmission rates of 41% for critical limb ischemia. Evidence on humanistic burden, though limited, showed significant declines in mental health and quality of life among patients with CVD. Concomitant CVD and advanced CKD or kidney failure substantially elevates the economic and humanistic burden compared to CVD or CKD alone, driving higher costs, increased healthcare utilization, and impaired quality of life. Targeted strategies addressing cardiovascular risk in patients with advanced CKD are essential to mitigate downstream clinical and financial consequences.
No takes yet. Share an insight, caveat, or question.
Floege et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: